Baron Funds, an investment management company, released its fourth-quarter investor letter for the “Baron Health Care Fund”. A copy of the letter can be downloaded here. The fund rose 13.10% (Institutional Shares) in the quarter, compared to a 11.92% gain for the Russell 3000 Health Care Index (benchmark) and a 2.40% gain for the Russell 3000 Index (the Index). The Fund returned 10.28% for the full year, compared to 14.56% and 17.15% gains for the indexes, respectively. Strong stock selection in biotechnol ...

Arcutis Biotherapeutics develops topical therapies for chronic skin conditions, with a portfolio targeting psoriasis and atopic dermatitis.On February 5, Tejara Capital reported selling out of Arcutis Biotherapeutics (ARQT 0.04%), unloading 520,503 shares in an estimated $9.81 million trade based on quarterly average pricing.What happenedAccording to a U.S. Securities and Exchange Commission (SEC) filing dated February 5, Tejara Capital reported selling its entire holding of 520,503 shares in Arcutis Biothe ...

Arcutis Biotherapeutics Inc. (ARQT), on Monday, announced that its phase 2 study evaluating ZORYVE cream 0.05% in infants aged 3 months to less than 24 months with atopic dermatitis has yielded positive topline results.In the phase 2 study, dubbed INTEGUMENT-INFANT, which enrolled 101 infants, 58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4. Moreover, the product was well tolerated and demonstrated a safety profile consistent with ...

58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a safety profile consistent with previous studies, with no new safety signals identified through 4 weeks of treatmentAtopic dermatitis impacts 9.6 million children in the United States; up to 60% of children with atopic dermatitis develop symptoms within their first yearThe Company plans to submit a supplemental New ...

Arcutis Biotherapeutics (ARQT) announced that on January 23, 2026, the Company and Kowa Pharmaceuticals America mutually agreed to terminate their promotion agreement. The agreement covered sales and promotion of ZORYVE by Kowa to primary care physicians and pediatricians in the United States. Following the termination, Arcutis plans to assume responsibility for sales and promotion of ZORYVE in the pediatric and primary care settings. The Company is finalizing its plans for promotion to these clinicians an ...

WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that on January 23, 2026, the Company and Kowa Pharmaceuticals America, Inc. mutually agreed to terminate their promotion agreement. The agreement covered sales and promotion of ZORYVE® (roflumilast) by Kowa to primary care physicians and pediatricians in the United States. Fo ...

Core Insights - Arcutis Biotherapeutics, Inc. will report its fourth quarter and full year 2025 financial results on February 25, 2026, after U.S. markets close, and will host a conference call at 4:30 p.m. ET on the same day [1] - The company will also participate in the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026, at 11:30 a.m. ET [2] Company Overview - Arcutis Biotherapeutics is a commercial-stage medical dermatology company focused on innovations for immune-mediated dermatological diseases, with a portfolio of advanced targeted topicals approved for three major inflammatory skin diseases [3] - The company utilizes a unique dermatology development platform and expertise to create differentiated therapies targeting biologically validated targets, resulting in a robust pipeline for various inflammatory dermatological conditions [3]

Core Insights - Arcutis Biotherapeutics, Inc. has released findings from a nationwide survey on patient perceptions regarding the use of topical steroids for chronic inflammatory skin diseases, highlighting a significant focus on reactive treatment rather than proactive management strategies [1][2][3] Group 1: Survey Findings - The survey involved 1,000 adults and 500 parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis, revealing that most treatment plans are reactive, aimed at managing flare-ups rather than preventing them [3][5] - Concerns about the side effects of topical steroids are prevalent, with nearly 9 in 10 respondents expressing worry about potential short- or long-term effects [5][6] - A significant portion of adults (72%) and children (80%) reported experiencing uncontrolled disease at least once a month, indicating a high frequency of flare-ups [6] Group 2: Emotional and Social Impact - The emotional and mental burden of living with these conditions is substantial, with many adults and children experiencing discomfort, frustration, and anxiety when their skin condition is uncontrolled [6][10] - The survey indicates that nearly half of adults (47%) have avoided social interactions due to their condition, and over half of children have missed school or social activities [6][7] - Even when symptoms are managed, a majority still feel self-conscious and anxious about potential future flare-ups, with only 20% of adults and 19% of parents feeling completely confident in their treatment plans [10] Group 3: Industry Implications - The findings suggest a critical opportunity for the dermatology community to shift towards more proactive disease management strategies, moving away from the traditional episodic care model [9] - There is a growing consensus among dermatology professionals regarding the risks associated with long-term steroid use, emphasizing the need for alternative treatment options that provide sustained relief [9] - Arcutis Biotherapeutics aims to address these challenges by developing innovative therapies that meet the needs of patients with chronic inflammatory skin diseases [15]

Continued strong growth of ZORYVE® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 millionAdvancement of ZORYVE indication-expansion strategy beginning with ongoing Phase 2 proof-of-concept trials in vitiligo and hidradenitis suppurativaInitiation of clinical development program for ARQ-234 in atopic dermatitisTransition to positive cash flows enables investment to both accelerate growth of ZORYVE franchise and advance pipeline WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWS ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Compass Therapeutics, Inc. (CMPX) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Compass Therapeutics, Inc. is one of 946 individual stocks in the Medi ...